ESMO: Daiichi unveils first early peek at next-gen ADC as analysts see strong data against rivals

After the success of its HER2 Enhertu, the centerpiece of its $6.9 billion deal with AstraZeneca in 2019 and now approved in certain breast cancers, the Japanese pharma has been keen to keep pushing on with its ADC pipeline.

Early Friday morning at the European Society of Medical Oncology Congress 2021, we got a glimpse of its fourth ADC, known simply as DS-7300, which works as a B7-H3 directed DXd antibody, in what is its first human data (PDF).